ClinicalTrials.gg
RecruitingNCT07156253Updated Sep 5, 2025

Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of SYN818 and Olaparib will be administered in Metastatic Solid Tumor, Ovarian Cancer and Breast Cancer, sponsored by Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 485 studies in Neoplasm Metastasis with a site in China — 222 open to participants now, 263 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Planned enrollment
176th of 401
110 · median 90
Started
2025
with 61 others
Phase 1
93 of 485
47 open now
Primary completion
2028-08
later than 219 of 262 live
Registered
400th of 485
by date

Among the 485 studies in Neoplasm Metastasis with a site in China, this one is the 176th largest by planned enrollment of the 401 interventional ones that give a count, is one of 62 that started in 2025, is one of 93 in phase 1, reaches primary completion later than 219 of the 262 other live ones, and was the 400th registered.

Neoplasm Metastasis

4,048 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

222 of the 485 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

217 more — sign in →

All 222 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 691 Neoplasm Metastasis studies recruiting now, 538 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 485 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with locally advanced or metastatic solid tumors

Read the detailed description

This study is a Phase Ib, open-label, multicentre study of SYN818 with Olaparib administered orally in patients with locally advanced or metastatic solid tumors harboring mutations in BRCA and/or defects in the homologous recombination repair (HRR) pathway

03

Conditions studied

  • Metastatic Solid Tumor
  • Ovarian Cancer
  • Breast Cancer
  • BRCA 1 /2 and / or HRD
  • Advanced Solid Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having signed the written Form (ICF);
  • Male or female aged ≥18 years;
  • ≥12 weeks;
  • (ECOG) Performance Score 0 or 1;
  • Participant has a confirmed diagnosis of advanced or solid tumor and has exhausted all standard-of-care treatment options, with documented BRCA mutations and/or homologous recombination repair deficiency (Part 1).
  • Participant has histologically or cytologically confirmed locally advanced or metastatic epithelial ovarian cancer or -negative breast cancer, with documented BRCA mutations and/or homologous recombination repair deficiency (Part 2).
  • At least one according to (RECIST) v1.1;
  • No serious hematological, cardiopulmonary, or liver or kidney diseases other than the primary disease;
  • Adequate organ function and bone marrow function.

Exclusion criteria

Exclusion Criteria:

  • Previous or current use of DNA Polymerase Theta (POLQ) inhibitors;
  • Current or previous other unless treated radically and with no evidence of recurrence or within the past 5 years;
  • Central nervous system (CNS) metastasis or meningeal metastasis with clinical symptoms, or other evidence indicating that or meningeal metastasis has not been adequately controlled;
  • Patients with Myelodysplastic syndrome (MDS)/Acute myeloid leukemia (AML) or with features suggestive of MDS/AML;
  • Dysphagia or nausea and vomiting, malabsorption, extracorporeal biliary shunts, or gastrointestinal disorders that affect drug absorption, e.g., Crohn's disease, ulcerative colitis, or short bowel syndrome, or other malabsorption conditions;
  • Treatment with an anti-cancer small molecule within 5 half-lives (t1/2), or 2 weeks, whichever is shorter;
  • History of use within 2 weeks prior to the first dose of the study treatment and need to use protocol-prohibited potent inhibitors or potent inducers of cytochrome P450 (CYP) 3A4/BCRP/P-gp during the study;
  • Serious systemic diseases or laboratory abnormalities or other conditions that, at the Investigator's discretion, will make it unsuitable for the patient to participate in this clinical trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    SYN818 combination with Olaparib

    Drug: SYN818 and Olaparib will be administered

Interventions

  • DrugSYN818 and Olaparib will be administered

    Patients will orally receive SYN818 and Olaparib

This study also gives Olaparib. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    MTD is defined as the maximum dose level at which ≤1 patient have dose limiting toxicities (DLTs) during the DLT observation period, and it should be determined with 6 evaluable patients.

    Time frame: Up to 3 years

  2. Number of participants with Dose Limiting Toxicities (DLTs)

    Severity of adverse events as assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: From first dose of study treatment until the end of Cycle 1 (each cycle is 21-days)

  3. Number of participants experiencing adverse events (AEs)/serious adverse events (SAEs)

    Number of participants with incidence of adverse events and with serious adverse events including changes from baseline in laboratory parameters, vital signs, Electrocardiogram (ECG), and physical examination, etc.

    Time frame: From time of information consent to 30 days post last dose, up to 3 years

Secondary outcomes

  1. Pharmacokinetic (PK) parameters

    To characterize the PK Peak Plasma Concentration (Cmax) of the SYN818 and Olaparib combination therapy

    Time frame: Up to 3 years

  2. Pharmacokinetic (PK) parameters

    To characterize the PK Time to Peak drug Concentration (Tmax) of the SYN818 and Olaparib combination therapy

    Time frame: Up to 3 years

  3. Pharmacokinetic (PK) parameters

    To characterize the PK Area under the plasma concentration versus time curve (AUC) of the combination therapy of SYN818 and Olaparib

    Time frame: Up to 3 years

  4. Pharmacokinetic (PK) parameters

    To characterize the PK profile of the combination therapy of SYN818 and Olaparib by measuring elimination half-life (t1/2)

    Time frame: Up to 3 years

  5. Objective Response Rate (ORR)

    ORR is defined as proportion of patients who achieved complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 recorded from first investigational product treatment until disease progression or death due to any cause. The confirmation of response for patients who has PR or CR at first time should be performed by at least 4 weeks. For castration-resistant prostate cancer (CRPC) patients, bone lesion will be assessed according to Prostate Cancer Working Group 3 (PCWG3) criteria.

    Time frame: Up to 3 years

  6. Duration of Response (DoR) and Time to Response (TTR)

    DOR is defined, for patients with an objective response, as the time from first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or death due to any cause.

    Time frame: Up to 3 years

  7. Progression Free Survival (PFS)

    PFS is defined as the time from the first study treatment to the date of the first documentation of objective progression of disease (PD) or death due to any cause.

    Time frame: Up to 3 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Aug 2028, 35 months later.

Of 288 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 35 months is below that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 5, 2025
StartEst.
Aug 26, 2025
Primary completionEst.
Aug 25, 2028
CompletionEst.
Feb 25, 2029
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07156253
Lead sponsor
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Responsible party
Sponsor
First posted
Sep 5, 2025
Start date
Aug 26, 2025 (estimated)
Primary completion
Aug 25, 2028 (estimated)
Completion
Feb 25, 2029 (estimated)
Last update
Sep 5, 2025

Study contacts

Duo Wu
Contact
wuduo@synrx.cn
+86-571-86360796

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion